Peer-reviewedCC BYClinical medicine (London, England)
Redefining care for IDH-mutant low-grade gliomas: Clinical implications of the INDIGO trial and updated guidelines
Related
- Redefining drug-induced tremor: a mechanism-based framework for clinical and etiological assessment
- Molecular Reclassification of Diffuse Gliomas: A Feasibility Study of Clinical Features and Survival Outcomes in Colombia
- Diffuse brainstem gliomas across the pediatric, adolescent, and adult age spectrum: Clinical and radiological features, molecular profile, and determinants of survival in a multicenter retrospective cohort of 42 patients.
- Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
- Thrombophilia Testing After VTE and in Related Clinical Contexts: Is It Necessary, and Does It Change Management? Appraisal of Evidence, Guidelines, and Clinical Yield
BibTeX
@article{anon2026redefining,
title = {{Redefining care for IDH-mutant low-grade gliomas: Clinical implications of the INDIGO trial and updated guidelines}},
journal = {Clinical medicine (London, England)},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13730223},
note = {CC BY},
}
RIS
TY - JOUR
TI - Redefining care for IDH-mutant low-grade gliomas: Clinical implications of the INDIGO trial and updated guidelines
PY - 2026
DA - 2026/09/01
JO - Clinical medicine (London, England)
UR - https://europepmc.org/article/PMC/PMC13730223
SN - 1470-2118
SN - 1473-4893
ER -